Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Outcomes and management strategies of pregnancies after heart and lung transplantation across Europe.JHLT open · 2026
   Article
2. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.American journal of respiratory and critical care medicine · 2023
   Article
3. Changing racial and ethnic differences for lung transplantation in cystic fibrosis.Pediatric transplantation · 2023
   Article

Corrections and comments

• Comment on
  Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.2022
• Comment on
  Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two2022

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as